The monocyte-macrophage system is regarded as a network of specialised phagocytic cells which are widely scattered throughout the body.' These cells include peripheral blood monocytes, Kupffer cells of the liver, microglial cells of the brain, macrophages of lymph node and spleen, and fixed tissue macrophages in various other human tissues. Cells of the monocytemacrophage system, however, do not include nonlymphoid mononuclear cells known as dendritic cells. 2 There is evidence that peripheral blood monocytes originate from bone marrow precursor cells3 and that tissue macrophages are derived from circulating monocytes.4 Bone marrow precursor cells therefore serve as the cells of origin for peripheral blood monocytes and tissue macrophages.
Cells of the monocyte-macrophage system are heterogeneous in terms of their morphology, cytochemistry, function and surface determinants.'56 As promonocytes mature into monocytes and then into tissue macrophages they increase in size. The ratio of the nucleus to that of the cytoplasm decreases and the number of lysosomes and IgG receptors increases. Functionally, mature macrophages have greater Accepted for publication 15 February 1988 ability to undergo phagocytosis and lymphocyte interaction than the less mature monocyte.' Furthermore, populations of resident macrophages in lymphoid tissues appear to differ from each other: resident macrophages thought to be accessory cells of the T cell immune response can be differentiated from accessory cells of the B cell immune response on the basis of different cellular determinants. 5 Various morphological, cytochemical, and immunological techniques have been used to identify cells of the monocyte-macrophage system.7 Among these techniques immunocytochemical labelling with monoclonal antibodies is one of the most sensitive and specific for identifying monocytes and tissue macrophages in non-neoplastic and neoplastic disorders.'0 Numerous monoclonal antibodies have been raised against cells of the monocyte-macrophage system"'5 but most of these react only with subpopulations of cells in the monocyte-macrophage system. Furthermore, many monoclonal antibodies raised against cells of the monocyte-macrophage system also react with determinants found on cells belonging to other cellular systems.'"
In this respect we describe our experience with a new monoclonal antibody (Yl /28A) raised against phyto-754 hemagglutinin activated peripheral blood mononuclear cells. Using an immunohistochemical technique, we showed that this monoclonal antibody reacts with peripheral blood monocytes and a range of tissue macrophages from patients with non-neoplastic and neoplastic disorders.
Material and methods
Blocks of fresh tissue were obtained from the histopathology department of the John Radcliffe Hospital at necropsy or at the time of surgical resection and were immediately snap frozen in liquid nitrogen and stored at -70°C until use. Tissues sampled from patients without neoplastic disorders included three lymph nodes with reactive hyperplasia, two sections of liver, and one section each of thymus, tonsil, spleen, liver, colon, kidney, heart, brain, striated muscle, thyroid, lung and skin. Tissues sampled from patients with neoplastic diseases included eight cases of non-Hodgkin's lymphoma, five cases of Hodgkin's lymphoma, six cases of squamous cell carcinoma of the bronchus, and one case of adenocarcinoma of the breast.
Cryostat sections (6 pm) were prepared from these frozen tissues and stored (wrapped in aluminium foil) at -20°C until staining.
Samples ofperipheral blood and bone marrow were obtained from patients attending the haematology department of the John Radcliffe Hospital. The samples were drawn into ethylene diamine tetra-acetic acid or heparin anticoagulant and either push films or cytocentrifuge films ofmononuclear cells separated on Triosil-Ficoll were prepared. ' Three days after an intravenous injection of 1 5 x 106 PHA stimulated blasts spleen cells from the mouse (1 8 x 10') were fused with 1-8 x I07 cells from the NS-1 myeloma cell line.'7 After 14 days the cultures were inspected for growth and the supematant fluid was screened for specific reactivity on cryostat sections of tonsil using the APAAP immunoalkaline phosphatase technique.'8 The clone Y1/28A, which selectively stained germinal centre macrophages, was then isolated by standard cloning techniques and established in long term tissue culture. In all experiments antibody Y1/82A was used in the form of spent tissue culture supernatant.
IMMUNOCHEMICAL LABELLING
Frozen tissue sections (6 pm) and blood and bone marrow films were labelled using the APAAP immunoalkaline phosphatase technique.'8 '9 Slides were fixed before APAAP staining in acetone (sections and cytocentrifuged preparations) or acetone:methanol.' IMMUNOFLUORESCENCE ANALYSIS Peripheral blood monocytes, granulocytes, and lymphocytes were analysed for expression of the Y1/82A determinant by indirect immunofluorescence using flow cytometry. Aliquots of normal peripheral blood mononuclear cells were incubated for 30 minutes with antibody Y1/82A at doubling dilutions in PBS from 1/5 through 1/80. Lymphocytes, monocytes, and granulocytes were analysed separately by gating on forward and right (900) (table 1) . In lymph nodes this included macrophages in the subcapsular and medullary sinuses, macrophages in germinal centres, mantle zones, and interfollicular areas (fig 1) . Lymphocytes, endothelial cells, and dendritic reticulum cells were unreactive. In the thymus, cortical and medullary macrophages were positive, but cortical and medullary thymocytes and thymic epithelial cells were negative. There was an intense staining reaction of the macrophages of the splenic cords (fig 2) . A few macrophages were present in germinal centres as well as around small arteries and capillaries.
Resident tissue macrophages in many non-lymphoid tissues were also reactive with monoclonal antibody Y1/82A. Kupffer cells and periportal macrophages of the liver (fig 3) , interstitial macrophages, and rare glomerular macrophages of the kidney, microglia cells, and perivascular macrophages in the brain, as well as fixed macrophages of colon, lung, heart, skin, striated muscle and thyroid were also all positive for monoclonal antibody Yl/82A. No other cells from these tissues were positive. In the lung, macrophages in the alveolar spaces (but not the alveolar walls) were positive (fig 4) .
In peripheral blood smears monocytes showed strong granular cytoplasmic labelling (table 1, fig 5) with monoclonal antibody Yl/82A. The number of positive granules varied considerably between individual monocytes; no evidence of surface membrane labelling was seen. Lymphocytes, neutrophils, and eosinophils were negative, with the exception of occasional blood smears in which some neutrophils fig 6) . In contrast, neoplastic cells from patients with non-Hodgkin's lymphoma, Hodgkin's disease, squamous cell carcinoma of the bronchus and adenocarcinoma of the breast were entirely negative. Groups of neoplastic cells, however, were often associated with large numbers of positively stained macrophages. Focal areas ofacute and chronic inflammation often accompanied the presence of the tumour cells and in these areas macrophages were intensely stained.
IMMUNOFLUORESCENCE ANALYSIS
Flow cytofluorographic analysis showed no membrane staining of granulocytes and lymphocytes with Y1/82A at any dilution. Membrane labelling of small numbers of monocytes ( < 3%) was observed but only at the lowest dilutions tested (1/5 and 1/10).
BIOCHEMICAL ANALYSIS OF THE Y1/82A
DETERMINANT Although the dot blotting experiments showed strongly immunoreactive Y1/82A antigen remaining in the high speed pellet, a weaker reaction was also observed with the supernatant.
Numerous attempts were made with the Western blotting technique to determine the molecular weight of the molecule(s) detected by Y1/82A. In some experiments a weak reaction was obtained against a reduced band, migrating with a molecular weight of about 45 000 Kd but this was not a consistently reproducible result.
Discussion
This study has shown that the monoclonal antibody Y1/82A raised against activated mononuclear cells reacts with a cytoplasmic determinant present in a very wide spectrum of cells from the monocytemacrophage system. These include peripheral blood and bone marrow monocytes as well as specialised tissue macrophages ofthe liver, spleen, lung, brain and skin. As some of these macrophages are in areas of inflammation or juxtaposed to tumour cells we can assume that many are activated. It seems that the Y1/82A antigen is therefore present in cells of the monocyte-macrophage system, both at different stages of maturation and also in various stages of activation.
Y1/82A clearly differentiates between cells of the 
